The ability to precisely edit the genomes of bacteria has long been a goal of microbiologists. Such technology would enable ...

The gene editing treatment targets the relatively common 1717-1G>A splicing mutation, which does not respond to many current CF therapies.

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death globally, with incidence continuing to rise in many regions. Despite advances in ...

A multi-lab team led by Gladstone Institutes has successfully adapted retron-based genome editing—previously limited to E. coli—for use in 14 additional bacterial species across three major branches ...

Artificial intelligence is accelerating advances across genetics, from precision genome editing to complete crop genome mapping and personalized disease risk prediction. Recent achievements include ...

A major collaboration involving nine labs, led by scientists at Gladstone Institutes, has transferred a particularly useful ...

This guidance emphasises the potential of NGS methods in mitigating safety risks associated with therapies incorporating ...

The Pairwise Fulcrum® platform includes proprietary gene editing tools, enzymes, and trait libraries that enable precise genetic changes, unlocking plants’ inherent potential and significantly ...

A platform approach to gene editing brings together design, manufacturing, validation, analytics, and regulatory considerations right from the start.

The US Food and Drug Administration (FDA) has released draft guidance on how sponsors can utilize next-generation sequencing ...